$0.98
6.31% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US74065P1012
Symbol
PRLD
Sector
Industry

Prelude Therapeutics Inc Stock price

$0.98
+0.18 22.95% 1M
+0.02 2.11% 6M
-0.29 22.98% YTD
-3.14 76.17% 1Y
-3.55 78.32% 3Y
-18.02 94.83% 5Y
-18.02 94.83% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.06 6.31%
ISIN
US74065P1012
Symbol
PRLD
Sector
Industry

Key metrics

Market capitalization $55.44m
Enterprise Value $-25.71m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.24
EV/Sales (TTM) EV/Sales -3.67
P/S ratio (TTM) P/S ratio 7.92
P/B ratio (TTM) P/B ratio 0.54
Revenue (TTM) Revenue $7.00m
EBIT (operating result TTM) EBIT $-139.98m
Free Cash Flow (TTM) Free Cash Flow $-105.85m
Cash position $99.07m
EPS (TTM) EPS $-1.83
P/E forward negative
Short interest 13.26%
Show more

Is Prelude Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Prelude Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Prelude Therapeutics Inc forecast:

3x Buy
75%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Prelude Therapeutics Inc forecast:

Buy
75%
Sell
25%

Financial data from Prelude Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7 7
-
100%
- Direct Costs 1.78 1.78
1% 1%
25%
5.22 5.22
397% 397%
75%
- Selling and Administrative Expenses 24 24
4% 4%
343%
- Research and Development Expense 119 119
10% 10%
1,706%
-138 -138
2% 2%
-1,974%
- Depreciation and Amortization 1.78 1.78
1% 1%
25%
EBIT (Operating Income) EBIT -140 -140
2% 2%
-2,000%
Net Profit -128 -128
2% 2%
-1,826%

In millions USD.

Don't miss a Thing! We will send you all news about Prelude Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prelude Therapeutics Inc Stock News

Neutral
GlobeNewsWire
14 days ago
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with ...
Neutral
GlobeNewsWire
20 days ago
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025.
Neutral
GlobeNewsWire
25 days ago
Preclinical data elucidating the mechanism of action of PRT3789, Prelude's first-in-class, highly selective SMARCA2 degrader currently in early clinical development
More Prelude Therapeutics Inc News

Company Profile

Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Head office United States
CEO Krishna Vaddi
Employees 131
Founded 2016
Website www.preludetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today